Figure 6.

Anti-tumor activity of albendazole in comparison with paclitaxel and in experimental bone metastasis of prostate cancer in vivo. (A, B) AT6.1 cells were inoculated intravenously five days prior to treatment of either paclitaxel or albendazole (ABZ). Shown are Kaplan Meier survival curve (A) and the average survival days (B) for each treatment group; N=10 per group, p<0.001 in vehicle vs. paclitaxel, vehicle vs. ABZ 100mg/kg, vehicle vs. ABZ 250mg/kg and paclitaxel vs. ABZ 250mg/kg. (C–E) Bone lesions of PC-3MLN4 cells were generated by intraosseous injection into the tibia of mice, before treatment with vehicle or 100 mg/kg albendazole (ABZ), three times a week for two weeks. (C) Representative photos of luciferase signal detected in each treatment group at the beginning and end of study. (D) Mean of luciferase signals detected in mice during treatment, as a measurement of tumor burden. (E) Representative images from X-ray (left) and micro-CT (right) analysis showing differences in radiographical characteristics of the bone lesions. Data shown are mean ± 95% confidence interval, N=10 per group. (F, G) AT6.1 cells were inoculated intravenously five days prior to treatment of either vehicle or nanoparticle-albendazole (NP-ABZ). Shown are Kaplan Meier survival curve (F) and the average survival days (G) for each treatment group; N=10 per group, p < 0.001 in vehicle vs. NP-ABZ.